Our team at Carillon Biopharma (CB) is comprised of a seasoned group of scientific, financial and legal experts focused on the establishment of a cancer immuno-nanotherapeutic venture based on a University of Washington-developed technology. Our nanotherapeutic, invented by Dr. Suzie Pun, Professor of Bioengineering and Chayanon Ngambenjawong, a Ph.D. candidate in Dr. Pun’s laboratory, specifically targets a critical immunosuppressive population of cells, M2-tumor associated macrophages (M2-TAMS), that reside within tumor microenvironments and promote tumor growth and metastasis. Clinical studies have shown that high M2 TAM levels are associated with poor prognosis. We have completed proof of concept studies demonstrating that elimination of M2 TAMs significantly reduced tumor size and prolonged survival in two different cancer animal models.
We envision the administration of our nanotherapeutic in combination with immunotherapeutic checkpoint inhibitors which have revolutionized the therapeutic landscape for growing numbers of cancers by increasing the overall and durable response rates over standard of care therapy rates. We hypothesize that our nanotherapeutic can boost these critical endpoints to make cancer a chronic disease to manage rather than a finite, mortal diagnosis.
We’re now 5 months into the CAI/NCI Nanotech Challenge, past the Business Plan phase (the most arduous thus far) and it has been quite a ride. The pace of the challenge has kept us on our toes, sometimes sprinting to meet deliverables, but the structure has ultimately been great in keeping us focused and in high learning mode! Rosemarie Truman and her CAI team have been very supportive and responsive. The weekly tutorials sessions they have organized have been invaluable, providing pearls of insights. We are eagerly awaiting the results of the Business Plan Phase!
We envision the administration of our nanotherapeutic in combination with immunotherapeutic checkpoint inhibitors which have revolutionized the therapeutic landscape for growing numbers of cancers by increasing the overall and durable response rates over standard of care therapy rates. We hypothesize that our nanotherapeutic can boost these critical endpoints to make cancer a chronic disease to manage rather than a finite, mortal diagnosis.
We’re now 5 months into the CAI/NCI Nanotech Challenge, past the Business Plan phase (the most arduous thus far) and it has been quite a ride. The pace of the challenge has kept us on our toes, sometimes sprinting to meet deliverables, but the structure has ultimately been great in keeping us focused and in high learning mode! Rosemarie Truman and her CAI team have been very supportive and responsive. The weekly tutorials sessions they have organized have been invaluable, providing pearls of insights. We are eagerly awaiting the results of the Business Plan Phase!
RSS Feed
